The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Sep. 21, 2010
Applicants:

Wylie Vale, La Jolla, CA (US);

Craig A. Harrison, Nunswading, AU;

Peter C. Gray, San Diego, CA (US);

Inventors:

Wylie Vale, La Jolla, CA (US);

Craig A. Harrison, Nunswading, AU;

Peter C. Gray, San Diego, CA (US);

Assignee:

Research Development Foundation, Carson City, NV (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); C07K 16/22 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 14/71 (2006.01); C07K 14/82 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 14/71 (2013.01); C07K 14/82 (2013.01);
Abstract

Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.


Find Patent Forward Citations

Loading…